Chengda Pharmaceuticals announced that the company has received the approval notification for the Daglielin active pharmaceutical ingredient chemical raw materials from the National Medical Products Administration. The Daglielin active pharmaceutical ingredient has passed the CDE technical review. Based on diet and exercise, this pharmaceutical can be used as a monotherapy to improve blood glucose control in adult patients with type 2 diabetes.
诚达药业：达格列净原料药通过CDE审批
Chengda Pharmaceuticals: The active pharmaceutical ingredient Daglielin has passed the CDE approval.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated